Five things for pharma marketers to know: Tuesday, April 25, 2017

Share this content:

1. Sanofi sued Mylan, alleging that the drugmaker engaged in anticompetitive practices to keep Sanofi's Auvi-Q, an EpiPen competitor, from gaining market share. Sanofi claims that Mylan ran up the price of the EpiPen to give pharmacy benefit managers a higher rebate so they would be more likely to give Mylan preferred status on their formularies. Sanofi no longer markets the Auvi-Q. (STAT)

2. Express Scripts will likely lose its biggest client, health insurer Anthem, when the contract ends in 2019. Anthem is suing Express Scripts for allegedly overcharging it for prescription drugs. (St. Louis Post-Dispatch)

3. Marc Speichert, GlaxoSmithKline's chief digital officer, and a previous Google exec, said advertisers should shorten the list of publishers they advertise with and grow relationships with them. (AdAge)

4. Roche and Merck spent the most on R&D in 2016. Amgen, AbbVie, and Takeda spent the least on R&D, when compared to the rest of the top 15 drugmakers, based on annual revenue in 2016. (Endpts)

5. Johnson and Johnson and Bayer are facing 18,000 lawsuits from U.S. patients, who say the blood thinner Xarelto caused internal bleeding. Xarelto brought in $3.2 billion in sales for Bayer and $2.2 billion for Johnson and Johnson last year. (Bloomberg)

Share this content:
Scroll down to see the next article